feedback

Course Director

Prof Eric Van Cutsem, MD, PhD
Prof Eric Van Cutsem, MD, PhD

University Hospitals Leuven
Leuven, Belgium

Faculty

Manish A. Shah
Manish A. Shah, MD

Center for Advanced Digestive Care
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
New York, New York

Neil H. Segal
Neil H. Segal, MD, PhD

Memorial Sloan Kettering Cancer Center
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Jul-03
Expiration Date:2019-Jul-02
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Immunotherapy has now become a key component of the treatment arsenal for colorectal and gastric or gastroesophageal junction cancers, and extensive investigations are underway to further refine and expand its role across the spectrum of gastrointestinal (GI) cancers. Identifying the patients most likely to benefit from immune-based therapies is essential for maximizing the potential of checkpoint inhibitors in the management of these tumors, and predictive biomarkers can be useful in this regard. What’s the latest from clinical trials assessing immunotherapies in different GI cancers? When and how should MSI/MMR status and PD-L1 expression testing be performed to guide clinical decisions? How should immunotherapy be optimally integrated into treatment plans for patients with GI cancers in real practice settings? These and other key topics are explored by top experts in this MasterClass and Practicum based on a recent live symposium held in Chicago.

Upon completion of this activity, participants should be better able to:
  • Discuss the mechanisms of action of immune checkpoint inhibitors and the rationale for checkpoint inhibition in the treatment of GI cancers
  • Describe the current guideline recommendations for MSI-H/dMMR testing, as well as implications for treatment selection for patients with metastatic MSI-H/dMMR GI cancer including CRC
  • Explain how current biomarkers for immunotherapy, including MSI-H/dMMR, PD-L1, TMB, and others across the spectrum of GI cancers, may inform treatment choices
  • Summarize recent clinical evidence on the safety and efficacy of checkpoint inhibitors in GI cancers
  • Implement strategies to identify and manage side effects associated with checkpoint inhibitors
  • Develop personalized treatment plans incorporating immune checkpoint inhibitors according to evidence- and guideline-based recommendations, including possible enrollment in a clinical trial for eligible patients with GI cancers

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, pathologists, and other healthcare professionals involved in the care of patients with gastrointestinal cancers.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 3, 2018 - July 2, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Prof Eric Van Cutsem, MD, PhD
Digestive Oncology
University Hospitals Leuven
Leuven, Belgium

Prof Eric Van Cutsem, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer AG; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Novartis AG; and Servier.
Grant/Research Support from Amgen Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Ipsen; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; Novartis AG; and Servier.
Prof Eric Van Cutsem, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: biomarker assays and immunotherapy agents or combinations for gastrointestinal cancers.

Faculty

Manish A. Shah, MD
Chief, Solid Tumor Oncology Service
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Bartlett Family Associate Professor of Gastrointestinal Oncology
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
New York, New York

Manish A. Shah, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Boston Biomedical.
Manish A. Shah, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: biomarker assays and immunotherapy agents or combinations for gastrointestinal cancers.

Neil H. Segal, MD, PhD
Assistant Attending, Gastrointestinal Oncology Service
Clinical Director, Immunotherapeutics Group
Memorial Sloan Kettering Cancer Center
New York, New York

Neil H. Segal, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Incyte Corporation; MedImmune/AstraZeneca; and Merck & Co., Inc.
Advisory Board for Boehringer Ingelheim GmbH; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd/Genentech, Inc.; MedImmune/AstraZeneca; Merck & Co., Inc.; and Pfizer Inc.
Neil H. Segal, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: biomarker assays and immunotherapy agents or combinations for gastrointestinal cancers.

CME Reviewer

Shaina Rozell, MD, MPH

Shaina Rozell, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Marie Becker, PhD
PVI, PeerView Institute for Medical Education

Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.